Publications by authors named "L De Moerlooze"
A multivalent RSV vaccine based on the modified vaccinia Ankara vector shows moderate protection against disease caused by RSV in older adults in a phase 3 clinical study.
Vaccine
December 2024
Article Synopsis
- - The study evaluated the efficacy of the MVA-BN-RSV vaccine, designed for older adults (≥60 years), against respiratory disease caused by RSV during the 2022-2023 season, involving 18,348 participants who received either the vaccine or a placebo.
- - Vaccine efficacy was reported as 42.9% against RSV-associated lower respiratory tract disease (LRTD) with 3 symptoms and 59.0% against LRTD with 2 symptoms; however, the primary endpoint was not met due to the lower confidence interval being below a predetermined success criterion.
- - The vaccine demonstrated mild to moderate side effects, showed promise by confirming immunogenicity (increased antibody responses), but provided
Article Synopsis
- The MVA-BN vaccine was widely used during the 2022 mpox outbreak, providing significant data on its safety, especially for intradermal use.
- A search of Bavarian Nordic's global safety database revealed 9,585 adverse events following immunization, with myocarditis and pericarditis occurring at a rate of less than 1 per 100,000 doses.
- The study concluded that while the vaccine is safe when given subcutaneously, intradermal administration is linked to a higher frequency of syncopal events, especially after its emergency use authorization in August 2022.*
Background: Respiratory syncytial virus (RSV) causes significant disease burden in older adults. MVA-BN-RSV is a novel poxvirus-vectored vaccine encoding internal and external RSV proteins.
Methods: In a phase 2a randomized double-blind, placebo-controlled trial, healthy participants aged 18 to 50 years received MVA-BN-RSV or placebo, then were challenged 4 weeks later with RSV-A Memphis 37b.
Article Synopsis
- Respiratory syncytial virus (RSV) is a major cause of respiratory infections in both children and older adults, with the latter group experiencing more severe disease due to incomplete natural immunity and age-related immune decline.
- Current RSV prophylaxis primarily targets infants, highlighting the need for vaccine development focused on older adults as a key demographic.
- While various vaccine candidates have shown promise in generating strong immune responses in clinical trials, further research is essential to enhance our understanding of RSV's immune interactions and to improve vaccine effectiveness tailored for older populations.
Background: Although modified vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccination is approved for smallpox and monkeypox prevention, immunological persistence and booster effects remain undescribed.
Methods: Participants naive to smallpox vaccination were randomized to 1 dose MVA-BN (1×MVA, n = 181), 2 doses MVA-BN (2×MVA, n = 183), or placebo (n = 181). Participants with previous smallpox vaccination received 1 MVA-BN booster (HSPX, n = 200).